Pub Date : 2021-01-01DOI: 10.32440/ar.2021.138.03.org03
L. Morales
Objective: To determine the association of structural and vascular parameters using optical coherence tomography (OCT) angiography (-A), in patients diagnosed with primary congenital glaucoma (PCG). Material and methods: 40 patients diagnosed with PCG were recruited (only one eye per patient was included). All study participants underwent a comprehensive ophthalmologic examination. Peripapillary and macular vascular measurements were obtained using AngioplexTM OCTA with a 4.5×4.5mm optic nerve head scan and 6x6mm macular scan. Structural parameters were collected: circumpapillary Retinal nerve fiber layer (cpRNFL) thickness (global and quadrants), ganglion cell-inner plexiform layer complex (GCL+IPL) thickness (average, minimum and sectors), rim area, average and vertical cup to disc (C/D) ratio and cup volume. Results: Global peripapillary values were: Mean flux index (FI) was 0.39 (0.05), mean perfusion density (pPD) was 42.57 (4.56) %, cpRNFL was 78.65 (22.50) microns, average c/p ratio (0.59 (0.18) and global GCL+IPL thickness was 71.71 (14.81) microns and minimum GCL+IPL thickness was 64.18 (18.63) microns. Statistical correlation was found between peripapillary structural, vascular and morphologic parameters (all p<0.023). Conclusion: OCTA measurements could offer useful and objective measurement of damage in early and severe congenital glaucoma, complementary to that offered by OCT.
{"title":"Association between vascular and structural parameters by optical coherence tomography angiography in primary congenital glaucoma","authors":"L. Morales","doi":"10.32440/ar.2021.138.03.org03","DOIUrl":"https://doi.org/10.32440/ar.2021.138.03.org03","url":null,"abstract":"Objective: To determine the association of structural and vascular parameters using optical coherence tomography (OCT) angiography (-A), in patients diagnosed with primary congenital glaucoma (PCG). Material and methods: 40 patients diagnosed with PCG were recruited (only one eye per patient was included). All study participants underwent a comprehensive ophthalmologic examination. Peripapillary and macular vascular measurements were obtained using AngioplexTM OCTA with a 4.5×4.5mm optic nerve head scan and 6x6mm macular scan. Structural parameters were collected: circumpapillary Retinal nerve fiber layer (cpRNFL) thickness (global and quadrants), ganglion cell-inner plexiform layer complex (GCL+IPL) thickness (average, minimum and sectors), rim area, average and vertical cup to disc (C/D) ratio and cup volume. Results: Global peripapillary values were: Mean flux index (FI) was 0.39 (0.05), mean perfusion density (pPD) was 42.57 (4.56) %, cpRNFL was 78.65 (22.50) microns, average c/p ratio (0.59 (0.18) and global GCL+IPL thickness was 71.71 (14.81) microns and minimum GCL+IPL thickness was 64.18 (18.63) microns. Statistical correlation was found between peripapillary structural, vascular and morphologic parameters (all p<0.023). Conclusion: OCTA measurements could offer useful and objective measurement of damage in early and severe congenital glaucoma, complementary to that offered by OCT.","PeriodicalId":75487,"journal":{"name":"Anales de la Real Academia Nacional de Medicina","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69672225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.32440/ar.2021.138.03.org01
F. Reinoso-Barbero
Background. In the last two decades, pediatric patients have been identified as particularly vulnerable to the acute and chronic consequences of pain, and valid tools have been developed for the measurement and treatment of chronic pain in children. However, we do not know to what extent Spanish children receive the indicated multidisciplinary treatment when suffering chronic pain. Material and methods. We review the results of a survey based on an electronic program through social networks provided by a specialized consultancy and developed by representatives of three scientific societies aimed at parents of children with persistent or recurrent pain lasting more than three months. Results. One hundred and fifty parents whose children met the inclusion criteria were included. Eighty percent of the participants suffered almost daily pain, but only 25% admitted moderate or severe pain intensity (score 5 or more on a scale of 0-10) with impairment of their quality of life. Some patients (18.7%) did not receive any treatment and of those who did, only about half received analgesic treatment. Only 8 of the 150 patients (5%) received multidisciplinary analgesic treatment. Conclusions. In Spain, we are currently far from offering optimal analgesic treatment to patients with pediatric chronic pain and, especially, very few patients receive multidisciplinary treatment (physiotherapy, psychotherapy and medical treatment). The new challenges that this situation produces are discussed: improvement of the training of the specialists involved, creation of pediatric pain units and use of new technologies.
{"title":"New challenges of paediatric chronic pain in Spain: Multidisciplinary treatment","authors":"F. Reinoso-Barbero","doi":"10.32440/ar.2021.138.03.org01","DOIUrl":"https://doi.org/10.32440/ar.2021.138.03.org01","url":null,"abstract":"Background. In the last two decades, pediatric patients have been identified as particularly vulnerable to the acute and chronic consequences of pain, and valid tools have been developed for the measurement and treatment of chronic pain in children. However, we do not know to what extent Spanish children receive the indicated multidisciplinary treatment when suffering chronic pain. Material and methods. We review the results of a survey based on an electronic program through social networks provided by a specialized consultancy and developed by representatives of three scientific societies aimed at parents of children with persistent or recurrent pain lasting more than three months. Results. One hundred and fifty parents whose children met the inclusion criteria were included. Eighty percent of the participants suffered almost daily pain, but only 25% admitted moderate or severe pain intensity (score 5 or more on a scale of 0-10) with impairment of their quality of life. Some patients (18.7%) did not receive any treatment and of those who did, only about half received analgesic treatment. Only 8 of the 150 patients (5%) received multidisciplinary analgesic treatment. Conclusions. In Spain, we are currently far from offering optimal analgesic treatment to patients with pediatric chronic pain and, especially, very few patients receive multidisciplinary treatment (physiotherapy, psychotherapy and medical treatment). The new challenges that this situation produces are discussed: improvement of the training of the specialists involved, creation of pediatric pain units and use of new technologies.","PeriodicalId":75487,"journal":{"name":"Anales de la Real Academia Nacional de Medicina","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69672152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.32440/ar.2021.138.03.rev02
J. R. Ribera Casado
Period 2020-2030 has been defined by the World Health Organization (WHO) as the «Healthy ageing decade». The aim of this review is to offer and comment the antecedents and reasons to justify this declaration. Main doctrinal concepts involved, as well as previous documents and recommended strategies are presented. The paper includes, also, the initial reactions that have taken place in Europe and in Spain about this declaration. Author underlines, as final remarks, the most selected messages of the review.
{"title":"A decade for healthy ageing. 2020-2030","authors":"J. R. Ribera Casado","doi":"10.32440/ar.2021.138.03.rev02","DOIUrl":"https://doi.org/10.32440/ar.2021.138.03.rev02","url":null,"abstract":"Period 2020-2030 has been defined by the World Health Organization (WHO) as the «Healthy ageing decade». The aim of this review is to offer and comment the antecedents and reasons to justify this declaration. Main doctrinal concepts involved, as well as previous documents and recommended strategies are presented. The paper includes, also, the initial reactions that have taken place in Europe and in Spain about this declaration. Author underlines, as final remarks, the most selected messages of the review.","PeriodicalId":75487,"journal":{"name":"Anales de la Real Academia Nacional de Medicina","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69672298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-30DOI: 10.32440/ar.2020.137.03.ed01
J. M. García Sagredo
{"title":"Genetic and Covid-19","authors":"J. M. García Sagredo","doi":"10.32440/ar.2020.137.03.ed01","DOIUrl":"https://doi.org/10.32440/ar.2020.137.03.ed01","url":null,"abstract":"","PeriodicalId":75487,"journal":{"name":"Anales de la Real Academia Nacional de Medicina","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69671690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-30DOI: 10.32440/AR.2020.137.03.REV02
A. Ortiz, M. Sánchez-Niño
Chronic kidney disease (CKD) is defined as an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73 m2 or evidence of kidney damage, such as albuminuria greater than 30 mg/g creatinuria, which persists more than 3 months. These cut-off points mark an increased risk of progression to the need for kidney replacement therapy and of the risk of premature death. Coronavirus disease-2019 (COVID-19) is no exception. The Global Burden of Disease collaboration identified CKD as the global most prevalent risk factor for severe COVID-19. The OpenSAFELY project analyzed the factors associated with death from COVID-19 in 17 million persons. Dialysis (adjusted hazard ratio [aHR] 3.69), organ transplantation (aHR 3.53) and CKD not on dialysis (aHR 2.52 for patients with eGFR <30 ml/min/1.73 m2) represent three of the four comorbidities associated with the highest risk of mortality from COVID-19. The risk associated with CKD is greater than the risk associated with diabetes mellitus (range aHR 1.31-1.95, depending on glycemic control) or chronic heart disease (aHR 1.17), whereas hypertension is not an independent risk factor for death from COVID-19 (aHR 0.89). The high prevalence of CKD, combined with the high risk of mortality from COVID-19 in CKD, requires urgent action to protect CKD patients from COVID-19 by offering the opportunity to participate in clinical trials of vaccines and treatments for COVID-19.
{"title":"Chronic kidney disease: the most prevalent risk factor and the risk factor that increases most the risk for lethal COVID-19","authors":"A. Ortiz, M. Sánchez-Niño","doi":"10.32440/AR.2020.137.03.REV02","DOIUrl":"https://doi.org/10.32440/AR.2020.137.03.REV02","url":null,"abstract":"Chronic kidney disease (CKD) is defined as an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73 m2 or evidence of kidney damage, such as albuminuria greater than 30 mg/g creatinuria, which persists more than 3 months. These cut-off points mark an increased risk of progression to the need for kidney replacement therapy and of the risk of premature death. Coronavirus disease-2019 (COVID-19) is no exception. The Global Burden of Disease collaboration identified CKD as the global most prevalent risk factor for severe COVID-19. The OpenSAFELY project analyzed the factors associated with death from COVID-19 in 17 million persons. Dialysis (adjusted hazard ratio [aHR] 3.69), organ transplantation (aHR 3.53) and CKD not on dialysis (aHR 2.52 for patients with eGFR <30 ml/min/1.73 m2) represent three of the four comorbidities associated with the highest risk of mortality from COVID-19. The risk associated with CKD is greater than the risk associated with diabetes mellitus (range aHR 1.31-1.95, depending on glycemic control) or chronic heart disease (aHR 1.17), whereas hypertension is not an independent risk factor for death from COVID-19 (aHR 0.89). The high prevalence of CKD, combined with the high risk of mortality from COVID-19 in CKD, requires urgent action to protect CKD patients from COVID-19 by offering the opportunity to participate in clinical trials of vaccines and treatments for COVID-19.","PeriodicalId":75487,"journal":{"name":"Anales de la Real Academia Nacional de Medicina","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43224596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-30DOI: 10.32440/AR.2020.137.03.REV06
J. M. Casado
The aim of this paper is to present some comments about ageism, and how it has been present along these months. Among the ageists´ manifestacions I underline the initial suggestion that COVID-19 is exclusively a disease of older adults in order to calm yunger people anxiety; the question of the nursing-homes and beside that, the social and health out of respect for residents along the pandemic period; the elders’ discrimination in guides and protocols; the negative image of this colective transmitted from the media; the absence of older adults in every forum of general discusión and in the decision committees; its absence in research protocols including clinical trials. Even the negative autoperception of the elders in this matter could be read as a pattern of ageism. Lastly, we offer some reflexion, open questions and suggestions on topìc.
{"title":"Ageism in pandemia’s times","authors":"J. M. Casado","doi":"10.32440/AR.2020.137.03.REV06","DOIUrl":"https://doi.org/10.32440/AR.2020.137.03.REV06","url":null,"abstract":"The aim of this paper is to present some comments about ageism, and how it has been present along these months. Among the ageists´ manifestacions I underline the initial suggestion that COVID-19 is exclusively a disease of older adults in order to calm yunger people anxiety; the question of the nursing-homes and beside that, the social and health out of respect for residents along the pandemic period; the elders’ discrimination in guides and protocols; the negative image of this colective transmitted from the media; the absence of older adults in every forum of general discusión and in the decision committees; its absence in research protocols including clinical trials. Even the negative autoperception of the elders in this matter could be read as a pattern of ageism. Lastly, we offer some reflexion, open questions and suggestions on topìc.","PeriodicalId":75487,"journal":{"name":"Anales de la Real Academia Nacional de Medicina","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41539842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-30DOI: 10.32440/AR.2020.137.03.REV03
M. I. L. Alcocer
SRAS COV-19 pandemic will have an impact in mental health, for general population, for health professionals, and for those who had suffered infection and for people with previous mental health disorders. Mental health problems after in pandemic can be considered similar as those that happened in a disasters or catastrophes situations, natural or human being induce; one of the principal characteristics is that they affect healthy persons. Up to now, there are some studies that considered that the incidence of mental health problems will raised up to 30%, and therefore is very important identified risk population, and vulnerability and protection factors to give this people the attention needed.
{"title":"Mental Health Impact of COVID-19 pandemic","authors":"M. I. L. Alcocer","doi":"10.32440/AR.2020.137.03.REV03","DOIUrl":"https://doi.org/10.32440/AR.2020.137.03.REV03","url":null,"abstract":"SRAS COV-19 pandemic will have an impact in mental health, for general population, for health professionals, and for those who had suffered infection and for people with previous mental health disorders.\u0000Mental health problems after in pandemic can be considered similar as those that happened in a disasters or catastrophes situations, natural or human being induce; one of the principal characteristics is that they affect healthy persons.\u0000Up to now, there are some studies that considered that the incidence of mental health problems will raised up to 30%, and therefore is very important identified risk population, and vulnerability and protection factors to give this people the attention needed.","PeriodicalId":75487,"journal":{"name":"Anales de la Real Academia Nacional de Medicina","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42545127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-30DOI: 10.32440/AR.2020.137.03.CC01
P. Estival, B. Colás, Yang Dai, F. González
The clinical course of a Paroxysmal Nocturnal Hemoglobinuria (PNH) patient receiving treatment with terminal complement by ravulizumab and SARS-CoV2 infection is described. The treatment commenced in January 2016 showing adequate tolerance and symptom resolution. In April 2020 an episode of breakthrough hemolysis is observed. Chest X-Ray revealed a right infection lobar infiltrate with SARS-CoV-2 positive PCR. The patient was afebril with normal oxygen saturation. He did not require standard disease treatment and presented eventual resolution, developing only mild symptoms. Neither PNH nor ravulizumab treatment seem to influence susceptibility to Covid-19 infection. It is possible that razulizumab, a complement inhibitor, may have played a beneficial role in the favorable clinical development.
{"title":"SARS-CoV-2 Infection in a patient with paroxysmal nocturnal haemoglobinuria (PNH) Treated with ravulizumab: a case report","authors":"P. Estival, B. Colás, Yang Dai, F. González","doi":"10.32440/AR.2020.137.03.CC01","DOIUrl":"https://doi.org/10.32440/AR.2020.137.03.CC01","url":null,"abstract":"The clinical course of a Paroxysmal Nocturnal Hemoglobinuria (PNH) patient receiving treatment with terminal complement by ravulizumab and SARS-CoV2 infection is described.\u0000The treatment commenced in January 2016 showing adequate tolerance and symptom resolution.\u0000In April 2020 an episode of breakthrough hemolysis is observed. Chest X-Ray revealed a right infection lobar infiltrate with SARS-CoV-2 positive PCR. The patient was afebril with normal oxygen saturation. He did not require standard disease treatment and presented eventual resolution, developing only mild symptoms.\u0000Neither PNH nor ravulizumab treatment seem to influence susceptibility to Covid-19 infection. It is possible that razulizumab, a complement inhibitor, may have played a beneficial role in the favorable clinical development.","PeriodicalId":75487,"journal":{"name":"Anales de la Real Academia Nacional de Medicina","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49232045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-30DOI: 10.32440/AR.2020.137.03.DOC01
C. Muñoz-Núñez, P. Calvillo-Batllés, Enrique Zaldívar Olmeda, V. Ripollés, L. Martí-Bonmatí
Coronavirus Disease 2019 (COVID-19) is a highly transmissible and pathogenic viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The target organ is the lung. This infection appeared in Wuhan (China) in December 2019 and the WHO considered it a pandemic in March 2020. One year after the first known cases, and although there is a great amount of scientific knowledge acquired of the disease, there are still some unanswered questions. As a matter of fact, there is a lack of knowledge about which patients will suffer sequels, what kind of morphological changes and sequel types will be expected, nor the grade of functional severity. It is known that other coronavirus pneumoniae caused pulmonary sequels and therefore they are expected in COVID-19. In this work we review several COVID-19 aspects related with the development and grading of mid- and long-term pulmonary sequels, including fibrosis and vascular changes, and strengthen the role of medical imaging in this evaluation.
{"title":"Radiological evaluation of pulmonary sequelae in COVID-19","authors":"C. Muñoz-Núñez, P. Calvillo-Batllés, Enrique Zaldívar Olmeda, V. Ripollés, L. Martí-Bonmatí","doi":"10.32440/AR.2020.137.03.DOC01","DOIUrl":"https://doi.org/10.32440/AR.2020.137.03.DOC01","url":null,"abstract":"Coronavirus Disease 2019 (COVID-19) is a highly transmissible and pathogenic viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The target organ is the lung. This infection appeared in Wuhan (China) in December 2019 and the WHO considered it a pandemic in March 2020. One year after the first known cases, and although there is a great amount of scientific knowledge acquired of the disease, there are still some unanswered questions. As a matter of fact, there is a lack of knowledge about which patients will suffer sequels, what kind of morphological changes and sequel types will be expected, nor the grade of functional severity. It is known that other coronavirus pneumoniae caused pulmonary sequels and therefore they are expected in COVID-19. In this work we review several COVID-19 aspects related with the development and grading of mid- and long-term pulmonary sequels, including fibrosis and vascular changes, and strengthen the role of medical imaging in this evaluation.","PeriodicalId":75487,"journal":{"name":"Anales de la Real Academia Nacional de Medicina","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44748934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-30DOI: 10.32440/AR.2020.137.02.REV11
A. Collazo-Lorduy, V. Calvo, M. Provencio
The outbreak of the new coronavirus disease (COVID-19) has become the greatest threat to public health worldwide. Oncological patients have an increased risk of infection due to their oncological disease, which supresses the immune system and mielosupressive effects of antincancer treatments. Throughout this article, the impact of COVID-19 in the oncological field will be reviewed, centering in diagnosis (susceptibility, differential diagnoses, delays in diagnosis in post-COVID era, triage systems); treatment (treatment of COVID-19 infection, surgeries, oncological treatments); impact in mortality and emotional impact. Maintaining quality of care in patients as vulnerable as cancer patients is a huge challenge in the face of possible outbreaks or future times when we have to face living with the infection but maintaining quality standards in healthcare.
{"title":"Impact of Covid-19 in the field of oncology","authors":"A. Collazo-Lorduy, V. Calvo, M. Provencio","doi":"10.32440/AR.2020.137.02.REV11","DOIUrl":"https://doi.org/10.32440/AR.2020.137.02.REV11","url":null,"abstract":"The outbreak of the new coronavirus disease (COVID-19) has become the greatest threat to public health worldwide. Oncological patients have an increased risk of infection due to their oncological disease, which supresses the immune system and mielosupressive effects of antincancer treatments.\u0000Throughout this article, the impact of COVID-19 in the oncological field will be reviewed, centering in diagnosis (susceptibility, differential diagnoses, delays in diagnosis in post-COVID era, triage systems); treatment (treatment of COVID-19 infection, surgeries, oncological treatments); impact in mortality and emotional impact.\u0000Maintaining quality of care in patients as vulnerable as cancer patients is a huge challenge in the face of possible outbreaks or future times when we have to face living with the infection but maintaining quality standards in healthcare.","PeriodicalId":75487,"journal":{"name":"Anales de la Real Academia Nacional de Medicina","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42467357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：